INZY

Inozyme Pharma Inc

INZY.US inozyme.com
Price N/A
USD · NASDAQ
52-week range
0.00
0.00
Market Cap
258.25M
P/E Ratio
0.00
Forward P/E
0.00
Book Value
0.49
Div. Yield
N/A
% Institutions
94.29%
% Insiders
1.26%

1 Year

-9.5%

3 Year

-13.4%

10 Year

-77.2%
Description

Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for rare diseases that affect bone health and blood vessel function. The company's lead product candidate consists of INZ-701, a soluble, recombinant, genetically engineered, and ENPP1 fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, and calciphylaxis, as well as patients with end-stage kidney disease receiving hemodialysis. It also develops Next Gen ERT for the treatment of ossification of the posterior longitudinal ligament (OPLL); and Gene therapy, a disease of the PPi-Adenosine Pathway. The company has license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Company Information

Company Name
Inozyme Pharma Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US45790W1080
CIK: 0001693011
CUSIP: 45790W108
Currency: USD
Full Time Employees: 67
Phone: 857 330 4340
Website: inozyme.com
Fiscal Year End: December
IPO Date: Jul 24, 2020
Description:

Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for rare diseases that affect bone health and blood vessel function. The company's lead product candidate consists of INZ-701, a soluble, recombinant, genetically engineered, and ENPP1 fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, and calciphylaxis, as well as patients with end-stage kidney disease receiving hemodialysis. It also develops Next Gen ERT for the treatment of ossification of the posterior longitudinal ligament (OPLL); and Gene therapy, a disease of the PPi-Adenosine Pathway. The company has license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Address:

321 Summer Street, Boston, MA, United States, 02210

People

Directors & Officers

Name Title Year Born
Dr. Douglas A. Treco Ph.D. CEO & Chairman 1958
Mr. Axel Bolte M.B.A., M.Sc. Co-Founder, Senior Advisor & Director 1972
Mr. Sanjay S. Subramanian M.B.A., M.S. CFO, Head of Business Development, Principal Accounting Officer & Corporate Secretary 1976
Dr. Matthew Winton Ph.D. Senior VP & COO 1978
Dr. Demetrios Braddock M.D., Ph.D. Co-Founder, Scientific Founder, Member of Scientific Advisory Board & Board Observer NA
Dr. Yves Sabbagh Ph.D. Senior VP, Chief Scientific Officer & Chair of the Scientific Advisory Board NA
Mr. Stefan Riley Director of Investor Relations NA
Ms. Gayle Gironda Senior VP & Chief People Officer NA
Mr. Stephen J. Di Palma M.B.A. Consultant 1959
Dr. Petra Duda M.D., Ph.D. Chief Medical Officer NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Apr 02, 2024 Douglas A Treco N/A Sale 7.52K $6.94 $52.21K
Aug 01, 2023 Pivotal Bioventure Partners Fu N/A Purchase 833.33K $4.80 $4.00M
May 11, 2023 Robert Lorne Hopfner N/A Purchase 219.23K $6.48 $1.42M
Mar 29, 2023 Robert Lorne Hopfner N/A Purchase 344.59K $4.54 $1.56M
Mar 27, 2023 Robert Lorne Hopfner N/A Purchase 51.07K $3.70 $188.97K
Dec 15, 2022 Henric Bjorn Bjarke N/A Purchase 21.50K $1.39 $29.89K

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Adage Capital Partners Gp LLC 5.16M Mar 31, 2025 7.99% $0.01 0.00%
Pivotal bioVenture Partners Investment Advisor LLC 4.49M Mar 31, 2025 6.96% $3.31 0.00%
Sofinnova Ventures 4.28M Jun 30, 2025 6.63% $1.05 0.00%
Affinity Asset Advisors, LLC 3.87M Mar 31, 2025 5.99% $0.34 -2.63%
BlackRock Inc 3.75M Mar 31, 2025 5.80% $0.00 -1.77%
Vanguard Group Inc 2.50M Jun 30, 2025 3.87% $0.00 -9.42%
NEA Management Company, LLC 2.44M Jun 30, 2025 3.78% $0.73 0.00%
Eckert Corp 2.19M Jun 30, 2025 3.39% $0.47 0.00%
Gabelli Funds LLC 1.46M Jun 30, 2025 2.26% $0.04 0.00%
Gardner Lewis Asset Management L P 1.26M Jun 30, 2025 1.95% $1.26 0.00%
Millennium Management LLC 1.24M Mar 31, 2025 1.93% $0.00 -33.87%
Geode Capital Management, LLC 1.23M Mar 31, 2025 1.91% $0.00 4.34%
FMR Inc 1.18M Mar 31, 2025 1.83% $0.00 -35.40%
Omers Administration Corp 1.12M Jun 30, 2025 1.73% $0.04 0.00%
State Street Corp 997.11K Mar 31, 2025 1.54% $0.00 -1.03%
Gabelli Securities Inc 617.00K Jun 30, 2025 0.96% $0.38 0.00%
Renaissance Technologies Corp 564.45K Mar 31, 2025 0.87% $0.00 33.95%
Woodline Partners LP 535.19K Jun 30, 2025 0.83% $0.01 -46.68%
Saturn V Capital Management LLC 499.25K Mar 31, 2025 0.77% $0.23 -63.68%
Sanofi 443.26K Jun 30, 2025 0.69% $1.01 0.00%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Fidelity Small Cap Index 545.22K 0.84% ▲ 2.75% May 31, 2025
2 GAMCO Intl SICAV Merger Arbtrg I (USD) 495.63K 0.77% ▲ 0.00% May 31, 2025
3 Fidelity Extended Market Index 266.16K 0.41% ▼ 0.26% Jun 30, 2025
4 AltShares Merger Arbitrage ETF 199.18K 0.31% ▲ 0.00% May 31, 2025
5 Extended Equity Market Fund K 107.58K 0.17% ▼ 1.96% Jun 30, 2025
6 Fidelity Total Market Index 86.33K 0.13% ▲ 0.00% Jun 30, 2025
7 Fidelity Series Total Market Index 71.35K 0.11% ▲ 6.10% Jun 30, 2025
8 1290 VT GAMCO Mergers & Acquisitions IB 60.00K 0.09% ▲ 50.00% Jun 30, 2025
9 Fidelity Small Cap Value Index 59.08K 0.09% ▲ 0.00% May 31, 2025
10 NT Col R2000 Val Idx Fd -DC -L -TierFour 58.60K 0.09% ▼ 43.52% Mar 31, 2025

Financial Highlights

Market Cap: $258.25M
EBITDA: $-104.74M
Book Value: $0.49
Earnings/Share: $-1.68
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -48.45%
ROE (TTM): -141.69%
Revenue (TTM): $0.00
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 0.00%

Valuation Metrics

Enterprise Value: $220.43M
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 64.56M
Shares Float: 29.98M
% Insiders: 1.26%
% Institutions: 94.29%
Short % Float: 5.67%

Stock Price History

1 Year Price History

3 Years Price History

10 Years Price History

Financial Charts

Revenue, Net Income & Operating Cash Flow (Yearly)

Revenue, Net Income & Operating Cash Flow (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$0.00
Gross Profit
subtotal
$0.00
SG&A
adjust
$-20.80M
R&D
adjust
$-83.23M
Operating Income
subtotal
$-104.03M
Other / Non-Operating Items
adjust
$2.01M
Net Income
subtotal
$-102.02M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about INZY.US!